Latest News

Haematological Malignancies - Lymphomas - Immunotherapy

2-Year ZUMA-1 Results Add Support For Axicabtagene Ciloleucel In Refractory Large B-Cell Lymphoma

  • 05 Dec 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Long-term follow-up of axicabtagene ciloleucel-treated patients with refractory large B-cell lymphoma suggests a role for the chimeric antigen receptor T-cell therapy in this setting...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof 2-Year ZUMA-1 Results Add Support For Axicabtagene Ciloleucel In Refractory Large B-Cell Lymphoma

Haematological Malignancies - Lymphomas - Immunotherapy

High Response Rates With Tisagenlecleucel In Adult Refractory DLBCL Patients

  • 04 Dec 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Phase II trial findings add support for the use of chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof High Response Rates With Tisagenlecleucel In Adult Refractory DLBCL Patients

Central Nervous System Malignancies - Complications/Toxicities of Treatment - Radiation Oncology

Low Risk Of Intracranial Malignancy After Stereotactic Radiosurgery

  • 30 Nov 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Incidence of radiation-associated intracranial malignancy following stereotactic radiosurgery is comparable to that of primary intracranial tumours in the general population...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Low Risk Of Intracranial Malignancy After Stereotactic Radiosurgery

Bone Sarcomas - Anticancer Agents

Regorafenib Shows ‘Clinically Meaningful’ Activity For Metastatic Osteosarcoma

  • 29 Nov 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Patients with progressive metastatic osteosarcoma may respond to second- or later-line treatment with regorafenib...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Regorafenib Shows ‘Clinically Meaningful’ Activity For Metastatic Osteosarcoma

Prostate Cancer - Anticancer Agents - Surgical Oncology - Radiation Oncology

High-Risk Prostate Cancer Survival Might Be Comparable With Surgical, Non-Surgical Strategies

  • 21 Nov 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Gleason 9–10 prostate cancer patients may derive similar survival from combination treatments using surgical and nonsurgical approaches...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof High-Risk Prostate Cancer Survival Might Be Comparable With Surgical, Non-Surgical Strategies

Head and Neck Cancers - Anticancer Agents - Radiation Oncology

Cetuximab Regimen Inferior To Cisplatin For HPV-Positive Oropharyngeal Carcinoma

  • 19 Nov 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Cisplatin plus radiation offers better survival outcomes and no worse toxicity than cetuximab plus radiation for patients with HPV-positive oropharyngeal carcinoma...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Cetuximab Regimen Inferior To Cisplatin For HPV-Positive Oropharyngeal Carcinoma

Breast Cancer - Personalised/Precision Medicine - Anticancer Agents

Omitting Anthracyclines May Be ‘Preferred’ Approach For Early HER2-Positive Breast cancer

  • 13 Nov 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Neoadjuvant paclitaxel and carboplatin with dual HER2 blockade may be sufficient for the first-line treatment of women with HER2-positive stage II or III breast cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Omitting Anthracyclines May Be ‘Preferred’ Approach For Early HER2-Positive Breast cancer

Immunotherapy - Head and Neck Cancers

Durvalumab Alone, Alongside Tremelimumab Feasible For Advanced PD-L1-Negative HNSCC

  • 06 Nov 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Durvalumab and tremelimumab given alone or in combination are compared for patients with recurrent or metastatic head and neck squamous cell carcinoma with little or no PD-L1 tumour expression...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Durvalumab Alone, Alongside Tremelimumab Feasible For Advanced PD-L1-Negative HNSCC

Anticancer Agents - Immunotherapy - Head and Neck Cancers

First-Line Pembrolizumab Plus Platinum-Based Chemotherapy ‘Standard Of Care’ For Advanced HNSCC

  • 02 Nov 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

First-line pembrolizumab plus platinum-based chemotherapy improves recurrent and metastatic head and neck squamous cell carcinoma survival compared with the EXTREME regimen...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof First-Line Pembrolizumab Plus Platinum-Based Chemotherapy ‘Standard Of Care’ For Advanced HNSCC

Anticancer Agents - Non-Small Cell Lung Cancer - Personalised/Precision Medicine

ALESIA Favours First-Line Alectinib For Asian ALK-Positive Advanced NSCLC Patients

  • 31 Oct 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Alectinib achieved significantly longer progression-free survival than crizotinib in treatment-naïve Asian patients with ALK-positive stage IIIB or IV non-small-cell lung cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof ALESIA Favours First-Line Alectinib For Asian ALK-Positive Advanced NSCLC Patients

Anticancer Agents - Immunotherapy

Avelumab Plus Axitinib ‘New First-Line Standard Of Care’ For Advanced RCC

  • 26 Oct 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Combining VEGFR and immune inhibition improves the outcomes of patients with a new diagnosis of advanced renal cell carcinoma...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Avelumab Plus Axitinib ‘New First-Line Standard Of Care’ For Advanced RCC

Prostate Cancer - Anticancer Agents - Radiation Oncology

Low Metastatic Burden May Point to Radiation Benefit For Newly Diagnosed Prostate Cancer

  • 23 Oct 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

STAMPEDE findings shed light on the use of radiotherapy for men with newly diagnosed metastatic prostate cancer beginning androgen deprivation therapy...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Low Metastatic Burden May Point to Radiation Benefit For Newly Diagnosed Prostate Cancer

Anticancer Agents - Breast Cancer - Immunotherapy

Atezolizumab Plus Nab-Paclitaxel Boost Metastatic Triple-Negative Breast Cancer Survival

  • 21 Oct 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

The addition of atezolizumab to nab-paclitaxel results in significantly longer progression-free survival for patients with treatment-naïve metastatic triple-negative breast cancer, especially among those with PD-L1-positive disease

Watch the ESMO Video Highlight on this study

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

 

view detailsof Atezolizumab Plus Nab-Paclitaxel Boost Metastatic Triple-Negative Breast Cancer Survival

Anticancer Agents - Breast Cancer

Serum Analysis Confirms Poor Tamoxifen Adherence Among Premenopausal Breast Cancer Patients

  • 20 Oct 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

A discrepancy has been detected between self-reported adherence to tamoxifen treatment and serum levels of the drug in premenopausal breast cancer patients...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Serum Analysis Confirms Poor Tamoxifen Adherence Among Premenopausal Breast Cancer Patients

Anticancer Agents - Prostate Cancer

Optimal Radiation–ADT Regimen Still Unclear For Intermediate–High-Risk Localised PC

  • 17 Oct 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

After more than 8 years of follow-up, researchers favour whole-pelvic radiotherapy plus neoadjuvant hormone therapy for the treatment of intermediate- and high-risk localised prostate cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Optimal Radiation–ADT Regimen Still Unclear For Intermediate–High-Risk Localised PC